



23 May 2016

Violetta Codreanu  
Australian Securities Exchange  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

Dear Violetta

### **ASX APPENDIX 4C QUERY**

We refer to the ASX price query we received issued by the ASX on Friday 20 May 2016.

1. Medlab Clinical Limited (Company) expects to continue having negative operating cash flows for the time being.
2. With regards to future cash inflows, the Company expects to receive the 2016 R&D Tax Concession in the first quarter, FY 2017. Based on last year, the Company received just over of \$800,000 and the Company does not see any reason why it would not be eligible for at least the same amount this year. At this point in time, the Company has not formally agreed on any capital raising but the Board will evaluate potential capital raising options. The Company is confident that it will be successful in being able to raise capital if required.
3. The Company expects to be able to continue its operations and to meet its business objectives. As outlined in the Shareholder Update (lodged Monday 23 May 2016), the Company has 17 Nutraceutical branded products, domestic and globally with another 4 products anticipated to reach the market in June 2016. The Company expects to continue to expand its Nutraceutical business thereby producing future cash flows.

4. The Company is in compliance with the Listing Rules and, in particular, Listing Rule 3.1 and there is no further information that should be given to the ASX about its financial condition that has not already been released to the market.

Yours Sincerely

A handwritten signature in black ink, appearing to read 'Alan Dworkin', with a stylized, cursive script.

Alan Dworkin  
Company Secretary



20 May 2016

Mr Alan Dworkin  
Chief Financial Officer and Company Secretary  
Medlab Clinical Limited  
66 McCauley Street  
Alexandria NSW 2015

By email

Dear Mr Dworkin

**Medlab Clinical Limited (the “Entity”): ASX Appendix 4C Query**

I refer to the Entity’s quarterly report in the form of Appendix 4C for the period ended 31 March 2016 lodged with ASX Market Announcements Platform and released on 28 April 2016 (the “Appendix 4C”).

ASX notes that the Entity has reported:

- negative net operating cash flows for the quarter of \$1,069,000; and
- cash at the end of the quarter of \$1,928,000.

It is possible to conclude on the basis of the information provided in the Appendix 4C that if the Entity were to continue to expend cash at the rate for the quarter indicated by the Appendix 4C, the Entity may not have sufficient cash to continue funding its operations. In view of that, please respond to each of the following questions:

1. Does the Entity expect that it will continue to have negative operating cash flows for the time being and, if not, why not?
2. Has the Entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
3. Does the Entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
4. Can the Entity confirm that it is in compliance with Listing Rule 3.1 and that there is no information that should be given to ASX about its financial condition in accordance with that Rule that has not already been released to the market?

Please also provide any other information that the Entity considers may be relevant to ASX forming an opinion on whether the Entity is in compliance with Listing Rule 12.2.

**When and where to send your response**

This request is made under, and in accordance with Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than 9:30am AEST on Wednesday, 25 May 2016. If we do

not have your response by then, ASX will have no choice but to consider suspending trading in the Entity's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, the Entity's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Listing Rule 3.1**

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

The obligation of the Entity to disclose information under Listing Rules 3.1 and 3.1A is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

In responding to this letter, you should have regard to the Entity's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, you should discuss with us whether it is appropriate to request a trading halt in the Entity's securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely,

*[Sent electronically without signature]*

Violetta Codreanu

**Adviser, Listings Compliance (Sydney)**